HUTCHMED (China) Ltd (STU:H7T1)
€ 16.1 0.5 (3.21%) Market Cap: 2.75 Bil Enterprise Value: 2.08 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 64/100

HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference Transcript

Oct 03, 2022 / 12:50PM GMT
Release Date Price: €8.7 (+0.58%)
Jason Matthew Gerberry
BofA Securities, Research Division - MD in US Equity Research

Hello, everybody. My name is Jason Gerberry, I'm one of the biotech analysts at BofA, and I'm pleased to kicking off BofA's first Precision Oncology Day Event. And we've assembled here for a collection of companies doing some of the more relevant clinical research in the field of precision oncology, and we've assembled a couple of expert panels to discuss relevant sector topics. So hopefully, you can join our lung cancer panel as well as our VC panel. And just to start things off, I just wanted to thank all of our participants in today's event for contributing. And I think what should be a pretty fruitful set of discussions.

And before we head it off to our first company fireside, I just wanted to say a few words as to why we view precision oncology as an interesting area from an investor perspective. First, despite a difficult market backdrop, particularly for biotech companies, we see the field of precision oncology is interesting given we have an accommodative regulatory backdrop, a number of targets that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot